Table 1 Baseline characteristics of the study population
Characteristics | DAPA-free (n = 645) | DAPA (n = 141) | P value |
|---|---|---|---|
Age (years) | 62.5 ± 13.5 | 60.6 ± 13.6 | 0.894 |
Sex, male, n (%) | 497 (77.1) | 105 (74.5) | 0.452 |
BMI (kg/m2) | 24.4 ± 3.9 | 26.2 ± 4.1 | 0.885 |
Smoking, n (%) | 319 (49.5) | 63 (44.7) | 0.281 |
Hypertension, n (%) | 393 (60.9) | 104 (73.8) | 0.005 |
Diabetes, n (%) | 96 (14.9) | 96 (68.1) | < 0.001 |
Cerebral infarction, n (%) | 40 (6.2) | 8 (5.7) | 0.867 |
In-hospital arhythmia, n (%) | 47 (7.3) | 12 (8.5) | 0.628 |
In-hospital AHF, n (%) | 57 (8.8) | 14 (9.9) | 0.694 |
Length of stay (days) | 8 (6.8–9) | 8 (7–10) | 0.220 |
STEMI, n (%) | 396 (61.4) | 99 (70.2) | 0.050 |
Stenting/POBA, n (%) | 627 (97.2) | 136 (96.5) | 0.398 |
Multivessel disease, n (%) | 616 (95.5) | 130 (92.2) | 0.106 |
Gensini score | 42 (21–69) | 49 (34–80) | 0.002 |
Biochemical test | |||
ALP (U/L) | 76.5 ± 25.6 | 77.9 ± 20.5 | 0.658 |
UA (umol/L) | 331 (280–400) | 324 (246–393) | 0.112 |
LDL-C (mmol/L) | 2.58 ± 0.88 | 2.77 ± 0.89 | 0.946 |
HDL-C (mmol/L) | 1.06 ± 0.30 | 1.01 ± 0.26 | 0.023 |
TC (mmol/L) | 4.3 ± 1.1 | 4.6 ± 1.4 | 0.677 |
TG (mmol/L) | 1.42 (1.05–1.99) | 1.76 (1.23–2.42) | 0.132 |
BNP (pg/mL) | 330 (99–1120) | 521 (145–1985) | < 0.001 |
CPK (U/L) | 534 (133–1446) | 486 (185–1276) | 0.028 |
CK-MB (U/L) | 51.4 (21.2–123.1) | 52.4 (21.9–109.9) | 0.055 |
HBDH (U/L) | 351 (196–672) | 337 (198–571) | 0.338 |
HbA1c (%) | 6.2 ± 1.2 | 7.9 ± 1.7 | < 0.001 |
Ccr (ml/min) | 66 ± 43 | 69 ± 33 | 0.917 |
Ultrasonic cardiogram | |||
LA (mm) | 3.9 ± 0.5 | 4.0 ± 0.5 | 0.553 |
LV (mm) | 5.1 ± 0.5 | 5.3 ± 0.6 | 0.015 |
EF (%) | 53 ± 9 | 49 ± 10 | 0.021 |
Pharmacological intervention | |||
β-block, n (%) | 364 (56.4) | 81 (57.4) | 0.817 |
ACEI/ARB, n (%) | 213 (33.0) | 39 (27.7) | 0.218 |
ARNI, n (%) | 126 (19.5) | 42 (29.8) | 0.007 |
MRA, n (%) | 50 (7.8) | 16 (11.3) | < 0.001 |